Key result
Primary prevention statins in older adults project to prevent ~173,000 MIs and CHD deaths.
Why the study?
Does statin therapy for primary prevention reduce myocardial infarction and coronary heart disease death in U.S. adults aged 75 to 94 years?
Does statin therapy for primary prevention reduce myocardial infarction and coronary heart disease death in U.S. adults aged 75 to 94 years?
Statins are projected to be cost-effective for primary prevention in adults aged 75 to 94 years, but cardiovascular benefits could be offset by small increases in geriatric-specific adverse effects.
No takes yet. Share an insight, caveat, or question.
Statin primary prevention may be cost-effective in adults 75-94; leaves open net benefit confirmation in RCTs accounting for geriatric harms.
Odden et al. (2015) studied Primary prevention of cardiovascular disease. Statins was evaluated on Myocardial infarction (MI), coronary heart disease (CHD) death, disability-adjusted life-years, and costs. Statin therapy for primary prevention in adults aged 75 to 94 years is projected to prevent 105,000 incident MIs and 68,000 CHD deaths over 10 years at $25,200 per disability-adjusted life-year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: